If you have been reading about Nuclear receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-18. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
== See also == List of distinct cell types in the adult human body List of human microbiota(Human microbiome) Composition of the human body Lists of human genes as well as all the list of the specific organ systems:like e. g: List of skeletal muscles of the human body, List of bones of the human skeleton, Tendon, List of nerves of the human body, List of arteries of the human body, List of veins of the human body
This alpha-ketoglutarate-dependent hydroxylase requires α-ketoglutaric acid, which is converted to succinic acid as a by-product. Aromadendrin is a precursor to many other derivatives. In some citrus fruits, naringenin is converted to prunin, the precursor to naringin, a compound which is responsible for the bitter taste of grapefruit.
==== Antibody-dependent cell-mediated cytotoxicity (ADCC) ==== Antibody-dependent cell-mediated cytotoxicity (ADCC) requires antibodies to bind to target cell surfaces. Antibodies are formed of a binding region (Fab) and the Fc region that can be detected by immune system cells via their Fc surface receptors. Fc receptors are found on many immune system cells, including NK cells. When NK cells encounter antibody-coated cells, the latter's Fc regions interact with their Fc receptors, releasing perforin and granzyme B to kill the tumor cell. Examples include rituximab, ofatumumab, elotuzumab, and alemtuzumab. Antibodies under development have altered Fc regions that have higher affinity for a specific type of Fc receptor, FcγRIIIA, which can dramatically increase effectiveness.
Sources: en.wikipedia.org
nuclear lamina A fibrous network of proteins lining the inner, nucleoplasmic surface of the nuclear envelope, composed of filaments similar to those that make up the cytoskeleton. It may function as a scaffold for the various contents of the nucleus including nuclear proteins and chromosomes.
During his life in retirement, from 1959 up to his death in 1973, Tolkien received steadily increasing public attention and literary fame. In 1961 his friend C. S. Lewis even nominated him for the Nobel Prize in Literature. The sales of his books were so profitable that he regretted that he had not chosen early retirement. In a letter in 1972 he deplored having become a cult figure, but admitted that "even the nose of a very modest idol ... cannot remain entirely untickled by the sweet smell of incense!" Fan attention became so intense that Tolkien had to take his phone number out of the public directory; eventually he and Edith moved to Bournemouth, which was then a seaside resort patronized by the British upper middle class. Tolkien's status as a best-selling author gave them easy entry into polite society, but Tolkien deeply missed the company of his fellow Inklings. Edith, however, was overjoyed to step into the role of a society hostess, which had been the reason that Tolkien selected Bournemouth in the first place. The genuine and deep affection between Ronald and Edith was demonstrated by their care about the other's health, in details like wrapping presents, in the generous way he gave up his life at Oxford so she could retire to Bournemouth, and in her pride in his becoming a famous author. They were also united by love for their children and grandchildren. In his retirement Tolkien was a consultant and translator for The Jerusalem Bible, published in 1966.
In contrast, Slavic settlements in southern Ukraine started to appear relatively early during Cuman rule, with the earliest, such as Oleshia, dating back to the 11th century. Early "Proto-Cossack" groups are generally reported to have come into existence within what is now Ukraine prior to the 13th century as the influence of Cumans grew weaker, although some have ascribed their origins to as early as the mid-8th century. Some historians suggest that the Cossack people were descended from East Slavs, Turks, Tatars, Circassians and others who settled or passed through the vast regions. There are archeological indications, according to Turkologists, that Cossacks are descendants of the native Cumans of Ukraine, who had lived there long before the Mongol invasion. Other theories expand upon that assertion to suggest that the first Cossacks were of Turkic origin. For example, according to Serhii Plokhy, the first Cossacks were of Turkic rather than Slavic stock. Christoph Baumer states that Cossack predecessors from the thirteenth century onward were mainly of Turkic stock, but from the sixteenth century the Cossacks were increasingly joined by Slavs such as Russians and Poles, Baltic Lithuanians and people from today's Ukraine, thus becoming a Slav-Tatar ethnic hybrid. The theory is also reflected in the Constitution of Pylyp Orlyk of 1710 and the Hrabianka Chronicle, which claims Khazar origins for the Cossacks. The Khazar origin myth became popular during the rule of Ivan Mazepa, a reaction against the Polish myth of Sarmatism.
Glutathione peroxidase 5 (GPx-5), also known as epididymal secretory glutathione peroxidase, is an enzyme that in humans is encoded by the GPX5 gene. GPx-5 belongs to the glutathione peroxidase family. It is specifically expressed in the epididymis in the mammalian male reproductive tract, and is androgen-regulated. Unlike mRNAs for other characterized glutathione peroxidases, this mRNA does not contain a selenocysteine (UGA) codon. Thus, the encoded protein is selenium-independent, and has been proposed to play a role in protecting the membranes of spermatozoa from the damaging effects of lipid peroxidation and/or preventing premature acrosome reaction. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.